Randomized, phase I studies to evaluate the safety, tolerability, and pharmacokinetics of an inhaled, TMEM16A potentiator, GDC-6988, in healthy subjects.

Ther Adv Respir Dis · 2025 · PMC12665028 · PMID 41318901

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

With salbutamol pretreatment, the negative changes from the daily baseline in mean FEV 1 were mitigated, with a positive trend observed for subjects on the 11.2 mg and 28 mg BID GDC-6988 and the placebo subjects.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.